Penn Medicine Provider
Dermatology
Ellen J. Kim, MD
5.0
(774)
Accepting new patients
Sees patients age 18 and up
Penn Dermatology Perelman

About me

  • Vice Chair, Clinical Operations
  • Director, Cutaneous Lymphoma Program and Photopheresis Service
  • Professor of Dermatology at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: University of Pennsylvania School of Medicine
  • Residency: Massachusetts General Hospital/Brigham and Women’s Hospital
  • Residency: Boston University School of Medicine
  • Fellowship: Boston University School of Medicine

What my patients think about me

Average Rating
5.0

774 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

June 2025
5.0
5.0
she is a great doctor
June 2025
5.0
5.0
very professional
May 2025
5.0
5.0
just very happy
May 2025
5.0
5.0
very professional and thorough

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Kim is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Marshall A, Kassim S, Brown-Korsah J, Raymundo C, Chang C, Hippe DS, Kim EJ, Shinohara MM. Black patients with Mycosis fungoides and Sézary Syndrome experience worse health-related quality of life: A cross-sectional study. Journal of the American Academy of Dermatology 2025-05-01 , J Am Acad Dermatol., 92(5): 2025,1100-1102


Elghawy O, Yang AG, Sussman JH, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Villasenor-Park J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK. Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome. , J Am Acad Dermatol., 92(3): 2025,634-636


Elghawy O, Yang AG, Sussman JH, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Villasenor-Park J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK. Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome. , J Am Acad Dermatol: 2024


Villasenor-Park J, Chung J, Kim EJ Cutaneous B-cell Lymphomas/Cutaneous Oncology , Hematology Oncology Clinics, 38(5): 2024,1111


Silva GS, Kim EJ, Barta SK, Chung J Immune-related adverse events associated with mogamulizumab: a comprehensive review of the literature , Expert Rev Anticancer Ther, 24(9): 2024,819-827


Asare C, Chen J, Ottevanger R, Scarisbrick J, Olsen EA, Tawa M, Thornton S, Kim E, Khan N, Larocca C, Shinohara MM. Systematic literature review to identify patient-reported outcome measures for patients with cutaneous T-cell lymphoma. , International Dermatology Outcomes Measures 11th Annual Meeting, Washington D.C.: 2024


Rastogi S, Kim EJ, Gelfand JM, Loren AW, Baumrin E Chronic graft-versus-host disease-associated muscle cramps: severity and response to immunomodulatory therapies , Transplant Cell Ther, 24: 2024


Weiner DW, Rastogi S, Lewis DJ, Cohen L, Choi S, Vittorio CC, Haun PL, Samimi SS, Villasenor-Park J, Bhansali RS, Chong EA, Landsburg DJ, Nasta SD, Schuster, Svoboda J, Kim EJ, Rook AH, Barta SK. Mogamulizumab Multimodality Therapy with Systemic Retinoids, Interferon, or Extracorporeal Photopheresis for Advanced Cutaneous T-Cell Lymphoma , Dermatologic Therapy: 2023


Bagot M, Kim YH, Geskin LJ, Ortiz-Romero P, Kim E, Mehta-Shah N, Dereure O, Oro S, Beylot-barry M, Dalle S, Jacobsen E, Lansigan F, Ram-Wolff C, Khodadoust MS, Battistella M, Gru A, Moins-Teisserenc H, Zinzani PL, Viott J, Paiva C, Muller M, Porcu P. Lacutumab in Patients with Relapsed and Refractory Sezary Syndrome: Results from the Tellomak Phase 2 Trial , American Society of Hematology Annual Meeting, San Diego, CA: 2023


Polgione B, Alexander-Savino CV, Kim EJ, Mangold AR, Desimone J, Wong H, Rumage AT, Donini O, Haulenbeek A, Schaber CJ, Straube R, Pullion C, Rook AH. HyBryte™ Use in Early-Stage Cutaneous T-cell Lymphoma , Front Drug Discov , 3: 2023